amantadine (Rx)

Brand and Other Names:
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

capsule/tablet

  • 100mg

syrup

  • 50mg/5mL
more...

Parkinson Disease

Serious illness or high dose of other antiparkinson agents: 100 mg/day PO initially; may be increased to 100 mg q12hr after at least 1 week

Up to 400 mg/day, but only in special circumstances

Drug-Induced Extrapyramidal Symptoms

100 mg PO q12hr; not to exceed 300 mg/day

Levodopa-induced Dyskinesia (Orphan)

Orphan designation for treatment of levodopa-induced dyskinesia

Sponsor

  • Osmotica Pharmaceutical Corporation; Regulatory, Clinical Operations & Legal; Lumina Station #2, Suite 209-A; Wilmington, NC 28403

Dosage Modifications

Renal impairment

  • CrCl 30-50 mL/min: 200 mg PO on 1st day, then 100 mg/day PO
  • CrCl 15-29 mL/min: 200 mg PO on 1st day, then 100 mg PO every other day
  • CrCl <15 mL/min; hemodialysis: 200 mg PO weekly

Dosage Forms & Strengths

capsule/tablet

  • 100mg

syrup

  • 50mg/5mL
more...

Influenza A Treatment

NOTE: Because of resistance, amantadine is no longer recommended for prophylaxis or treatment of influenza A; refer to current ACIP recommendations

1-9 years or <40 kg (any age): 5 mg/kg/day PO in single dose or divided q12 hr; not to exceed 150 mg/day

≥10 years and <40 kg: 5 mg/kg/day PO divided q12hr

≥10 years and ≥40 kg: 100 mg PO q12hr

Parkinson Disease

>65 years: Therapy should be based on renal function

Next:

Interactions

Interaction Checker

and amantadine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            1-10%

            Agitation

            Anorexia

            Anxiety

            Ataxia

            Confusion

            Constipation

            Depression

            Diarrhea

            Dizziness

            Dream abnormality

            Dry nose

            Fatigue

            Hallucinations

            Headache

            Insomnia

            Irritability

            Livedo reticularis

            Nausea

            Nervousness

            Orthostatic hypotension

            Peripheral edema

            Somnolence

            Xerostomia

            <1%

            Amnesia

            CHF

            Decreased libido

            Dyspnea

            Eczematoid dermatitis

            Euphoria

            Hyperkinesis

            Hypertension

            Instances of convulsions

            Leukopenia

            Neutropenia

            Oculogyric episodes

            Psychosis

            Rash

            Slurred speech

            Urinary retention

            Visual disturbances

            Vomiting

            Weakness

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity to amantadine, rimantadine

            Untreated narrow-angle glaucoma

            Breastfeeding

            Cautions

            Since 2008-09 influenza season, Centers for Disease Control and Prevention (CDC) advises against use for treatment or prophylaxis of influenza in US

            CHF, peripheral edema, orthostatic hypotension

            Renal impairment, liver disease

            Advanced age

            History of seizures, eczematoid rash, severe psychosis or psychoneurosis

            Dosages >200 mg/day

            Consider reducing anticholinergic dosages before initiating amantadine therapy

            Avoid abrupt withdrawal

            Risk of neuroleptic malignant syndrome (NMS) with dosage reduction or withdrawal

            May impair ability to perform hazardous tasks

            Possibility of reduced effectiveness after several months; may regain efficacy if dosage is increased

            Parkinson patients

            • Risk of uncontrollable sexual, gambling, or other urges
            • May be linked to higher melanoma risk
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy category: C

            Lactation: Drug enters breast milk; not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Prevents release of infectious viral nucleic acid

            May promote dopamine release from presynaptic fibers or block reuptake of dopamine into presynaptic neurons

            Absorption

            Bioavailability: 86-90%

            Onset: Within 48 hr (antidyskinetic)

            Peak plasma time: 2-4 hr

            Peak plasma concentration (100-mg single dose): 0.24 mcg/mL

            Distribution

            Protein bound: 67%

            Vd: 1.5-6.1 L/kg (normal renal function)

            Metabolism

            Not appreciably metabolized; small amounts of acetyl metabolite identified

            Elimination

            Half-life: 16 hr (average with normal renal function)

            Total body clearance: 0.2-0.3 L/hr/kg

            Excretion: Urine (80-90% unchanged) by glomerular filtration and tubular secretion

            Previous
            Next:

            Administration

            Oral Administration

            Administer daily dose in 2 divided doses to decrease adverse CNS effects

            Administer 2nd dose several hours before bedtime to minimize insomnia

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous